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Abstract
Background Infliximab and etarnecept are now widely used for treating severe psoriasis. However, these drugs,
especially infliximab, increased the risk of tuberculosis reactivation. Surprisingly, epidemiological data suggest that
the tuberculosis rate in patients taking infliximab in Sa˜o Paulo State, Brazil, is similar to that of some developed,
non-endemic countries.
Objective The aim of this study was to better understand the effect of infliximab on Mycobacterium tuberculosis
(Mtb) immune responses of psoriasis patients in an endemic setting (Brazil).
Methods We evaluated the tuberculosis-specific immune responses of severe psoriasis patients and healthy
individuals, both tuberculin skin test (TST) positive, in the presence ⁄ absence of infliximab. Patients had untreated
severe psoriasis, no co-morbidities affecting the immune responses and a TST >10 mm. Healthy TST+ (>10 mm)
individuals were evaluated in parallel. PBMC cultures from both groups were stimulated with different
Mycobacterium tuberculosis (Mtb) antigens (ESAT-6, 85B and Mtb lysate) and phytohemagglutinin, with or without
infliximab (5 lg ⁄mL). Parameters evaluated were TNF-a, IFN-c and IL-10 secretion by ELISA, overnight IFN-c
ELISpot and lymphocyte proliferative response (LPR).
Results Infliximab almost abolished TNF-a detection in PBMC supernatants of both groups. It also significantly
reduced the LPR to phytohemagglutinin and the Mtb antigens as well as the IFN-c levels secreted into day 5
supernatants in both groups. There was no concomitant exaggerated IL-10 secretion that could account for the
decreases in these responses. ELISpot showed that, contrasting with the central-memory responses above,
infliximab did not affect effector-memory INF-c-releasing T-cell numbers.
Conclusions Infliximab affected some, but not all aspects of the in vitro antituberculosis immune responses
tested. The preserved effector-memory responses, putatively related to exposure to environmental mycobacteria,
may help to explain the lower than expected susceptibility to tuberculosis reactivation in our setting.
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Introduction
Two TNF-a antagonists, infliximab (IFX) and etanercept (ETA),
have now been used for approximately 10 years for treating
patients with severe psoriasis with good results. In 2008, another
antagonist, adalimumab, has also been approved for treating pso-
riasis. These drugs, however, were associated with an increased
incidence of intracellular infections, especially pulmonary and
extra pulmonary tuberculosis (TB).1 In fact tumour necrosis factor
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alpha (TNF-a) plays a critical role in the control of TB immune
responses.2 It was soon noticed that the rate of TB was much
higher in association with IFX and adalimumab than with ETA,
probably reflecting their immunological effects due to differences
in their structures, pharmacokinetics and mechanisms of action,
adalimumab and IFX having similar structures and mechanisms of
action.1 As a consequence, several medical societies published
guidelines recommending screening and, upon evidence of a latent
infection, chemoprophylaxis for TB before starting treatment with
these drugs. Upon implementation of these recommendations, the
rate of TB among patients taking TNF-a antagonists for treating
immunomediated inflammatory diseases (IMID) decreased signifi-
cantly. This was well documented in Spain where the rate of TB
among TNF-a exposed patients fell from 522 to 117 per 100 000
patients-years. Nevertheless, it still remained several folds higher
than prevalence among the general population.3 In France, in the
period of 2004–2006, the rate of TB was 187.5 for patients with
IMID taking IFX (and 215 for those taking adalimumab), which is
twenty-fold higher than the rate of TB in the general population
(9 ⁄ 100 000 persons-year).4 Many reasons can account for these
persistently abnormal rates. Among them are failure to comply
with chemoprophylaxis,4,5 limited efficacy of the actual chemopro-
phylaxis regimens (able to reduce by 60% only the risk of TB reac-
tivation),6 and perhaps most importantly, false negative results
with the TST. In TB endemic areas, the TST misses up to 50% of
the patients with latent TB probably due to the immunological
imbalance underlying the IMIDs (EA Lima and G Benard, unpub-
lished data).7 In the French study, 43.5% of the IMID patients
who developed TB escaped the criteria for, and did not receive,
chemoprophylaxis.4 In Greece, a TB rate of 449 per 100 000
patients was estimated despite the implementation of the TB
screening recommendations.8 This raised serious concern with
regard to the use of TNF antagonists in TB endemic areas, such as
Brazil. High cost of the TNF antagonists has limited their use in
poor countries. However, in Brazil, the State Health Department
included the TNF-a antagonists in its high-cost medication pro-
gramme, facilitating their access to low-income patients. There-
fore, e.g., in 2009 a total of 6037 patients with IMID had access to
TNF-a antagonists in Sa˜o Paulo Sate. Surprisingly, preliminary
data suggest that the rate of TB in patients with IMID taking IFX
was 279.9 ⁄ 100 000 for the year 2009, i.e. 7.4 times higher than that
of the general population in the state for that year (37.9 ⁄ 100 000)
(TB Division, Center for Epidemiological Surveillance, Health
Department, Sa˜o Paulo State Government). This proportion is not
different (or even lower) than that observed in developed, coun-
tries with low TB endemicity, as discussed above. This number is
particularly intriguing because of the limitations of the TST as a
screening tool, and in addition, because it is estimated that at least
5% of the patients prescribed TNF antagonists do not undergo TB
screening (JS Carvalho, unpublished data).
To better understand the effect of TNF-a blockade with IFX on
the susceptibility to TB reactivation in severe psoriasis patients in
a TB endemic setting, we evaluated the in vitro M. tuberculosis
(Mtb)-specific immune responses of severe psoriasis patients and
healthy donors, both with a positive TST, in the presence or
absence of IFX.
Materials and methods
Patients and healthy donors
Patients were selected from a cohort of moderate to severe psoria-
sis patients admitted at our outpatient unit as described previ-
ously.9 Briefly, patients were >18 years of age, had fully active
lesions compromising >10% of the body surface, lack of co-
morbidities or treatments with agents known to interfere with the
immune system. All eleven patients selected for the study were
without systemic treatment for psoriasis for at least the last
3 months and were strong TST responders (>10 mm induration,
2 UT ⁄units PPD, Serum State Institute, Copenhagen, Denmark).
None of the TST responders had clinical or radiological evidence
of active TB. In parallel, 13 healthy adults, strong responders to
TST (>10 mm induration), were studied. All patients and healthy
individuals gave written informed consent. The study was
approved by the ethics committee of the Hospital das Clı´nicas da
Universidade de Sa˜o Paulo (protocol # 830 ⁄ 05).
Mycobacterium tuberculosis antigens preparation
Three different Mtb antigen preparations, one consisting of a
crude mixture of Mtb antigens and two purified, recombinant
Mtb proteins (Ag85 and ESAT-6), were produced as described
previously.9,10 The sonicated lysate (SAg) of M. tuberculosis H37Rv
was kindly donated by M. Palaci (Universidade Federal do Espı´rito
Santo, Brazil). The recombinant antigen 85B was obtained from
the Colorado State University through contract # BR0300; the
recombinant antigen ESAT-6 was overexpressed and purified as
described elsewhere.11
Lymphocyte stimulation tests
Lymphocyte proliferative response assays were carried out as
described previously.10 Briefly, peripheral blood mononuclear cells
(PBMCs) were isolated by Ficoll-Hypaque gradient (Sigma-
Aldrich, St. Louis, MO, USA), resuspended in RPMI-1640
(GIBCO-BRL, Gaithersburg, MD, USA) supplemented with
20 mmol ⁄L HEPES (GIBCO-BRL), 2 mmol ⁄L glutamine (GIB-
CO-BRL), 0.1 mmol ⁄L sodium pyruvate (GIBCO-BRL) and 10%
heat-inactivated human AB serum (Sigma-Aldrich) and plated in
96-wells plates in triplicates (2.5 · 105 cells per well). PBMCs were
cultured in triplicate wells in 5% CO2 at 37 C for 3 days with
phytohemagglutinin (PHA, 2.5 lg ⁄mL, Sigma-Aldrich) and for
6 days with ESAT-6 (5 lg ⁄mL), Ag85B (2.5 lg ⁄mL) and SAg
(5 lg ⁄mL), as described elsewhere.9 IFX (kindly donated by
Schering-Plough, Sa˜o Paulo, Brazil) was added at a final concen-
tration of 5 lg ⁄mL. PBMCs were pulsed with [3H]thymidine
(Amersham International, Buckinghamshire, UK) 18 h before
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harvest; radioactivity incorporation was measured using a beta-
counter (Betaplate 1205, Perkin-Elmer, Boston, MA, USA). A trip-
licate of wells with unstimulated cells served as background
proliferation. Results were analysed both as stimulation index (SI)
[ratio between the mean count (cpm) of the stimulated wells and
the mean count of the unstimulated wells], and Dcpm (cpm of the
stimulated wells minus cpm of the unstimulated wells), which
yielded similar results. Only results in SI are shown.
Quantification of IFN-c and IL-10 secretion in
supernatants using ELISA
Peripheral blood mononuclear cells cultures were set up as above;
supernatants were harvested at days 2 and 5 and stored in aliquots
at )80 C until use. TNF-a, IL-10 and IFN-c levels were quanti-
fied by ELISA (Pierce-Endogen, Rockford, IL, USA) according to
the manufacturer. The lower limit of detection of the assays was
10 pg ⁄mL.
ELISpot assay for IFN-c
The assay was performed and analysed as described previously.9
Briefly, Multiscreen-IP plates (Millipore Corporation, Bedford,
MA, USA) were coated with antihuman IFN-c monoclonal anti-
body (MAb) (4 lg ⁄mL, Pierce-Endogen) overnight at 4 C.
PBMCs were plated (2 · 105 cells ⁄well) in triplicates in the pres-
ence of PHA or Mtb antigens at the concentrations described
above, with or without IFX (5 lg ⁄mL), and left overnight at
37 C in 5% CO2. Plates were then washed and further incubated
for 2 h at 37 C with human IFN-c MAb biotin labelled (1 lg ⁄
mL, Pierce-Endogen). The reaction was revealed using strepto-
avidin-alkaline phosphatase (Pierce-Endogen) and BCIP ⁄NBT
substrate. The number of spot forming cells (SFC) ⁄ 1 · 106 for
each stimulus was counted using the software ImmunoSpot 3.2
(CTL ImmunoSpot S4 Analyzer, C.T.L., Cleveland, OH, USA).
Values were expressed after subtracting the background. The assay
was validated if the PHA wells gave >20 spots ⁄well.
Statistical analysis
The Wilcoxon matched pairs test (Graphpad Prisma 5, Microsoft,
USA) was used to compare the data with and without TNF-a
antagonist. Significance level was set at 0.05.
Results
Cultures of PBMC from TST+ psoriasis patients and TST+ healthy
individuals were stimulated with Mtb antigens and PHA, in the
presence or absence of therapeutic concentration of IFX (5 lg ⁄mL)
as indicated in Materials and methods. Mtb antigens were a soni-
cated lysate (SAg) of M. tuberculosis; the recombinant protein
85B, which has been used to elicit in vitro recall responses and as a
vaccine candidate, and whose homolog is present in all mycobacte-
ria; and the recombinant protein ESAT-6, which, in contrast, is
more specific because its encoding region is absent in most
environmental mycobacteria, including the BCG vaccine strain.
We first determined the effect of IFX on the TNF-a concentra-
tion released in the supernatants. Release of TNF-a by unstimu-
lated cells from patients and healthy individuals was undetectable
in the presence or absence of IFX (not shown). Figure 1 shows
that IFX almost abolished the detection of the cytokine released by
stimulated cells in both groups. Because lower amounts of TNF-a
were released by PBMCs of healthy individuals when stimulated
with ESAT-6 and 85Ag, their further reduction by IFX did not
reach statistical significance.
We then assessed the effect of IFX on the proliferative responses
of PBMCs. As shown in Fig. 2, patient and healthy individual
groups showed positive proliferative responses to the stimuli. IFX
significantly reduced the responses to all stimuli in both groups.
Interferon-c, together with TNF-a, is a key cytokine in the
development and stability of well-formed granulomas, the main
host mechanism for the containment of mycobacteria.12 Evalua-
tion of the IFN-c release by PBMC was carried out in two ways,
reflecting either the total amount of IFN-c produced or the num-
ber of IFN-c producing cells. First, we used the ELISpot assay to
Figure 1 Quantification of TNF-a production. TNF-a production
was quantified using ELISA in day 2 PBMC culture supernatants
from untreated TST+ severe psoriasis patients (n = 9) and TST+
healthy individuals (n = 9), stimulated with M. tuberculosis SAg,
Ag85B, ESAT-6 and PHA in the presence (white columns) or
absence (grey columns) of infliximab (IFX, 5 lg ⁄mL). Results are
shown as mean ± SE. *, P < 0.05; **, P < 0.01, Wilcoxon
matched pairs test. Non-stimulated wells had undetectable
levels of the cytokine.
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determine the number of cells releasing the cytokine rapidly early
(overnight) after being challenged with the respective stimuli, a
feature of effector memory T-cells (Tem).13 In both groups, as
expected for TST+ subjects, the Mtb antigens induced high fre-
quencies of IFN-c-secreting cells; these frequencies remained unal-
tered in the presence of IFX for most subjects tested (Fig. 3). The
same held true for the positive control, PHA. Secondly, the IFN-c
released in supernatants after 6 days was measured using ELISA;
in this case, it is expected that the cytokine is produced mostly by
central memory T cells (Tcm), which require several days after
challenge to reach their maximum in cytokine secretion.14 IFX
reduced the total IFN-c secretion by the TST+ psoriasis patients’
cells; this reduction was statistically significant for stimulation with
PHA, Ag85B and SAg but not with ESAT-6. The reduction in total
IFN-c secretion was less consistent in the healthy individuals and
was statistically significant only with Ag85B (Fig. 4).
To determine whether the inhibitory effects on the IFN-c secre-
tion and LPR were due to exaggerated IL-10 secretion, we mea-
sured the IL-10 released on day-2 supernatants. Except for PHA,
the amounts of IL-10 induced by the Mtb antigens were 1 log
lower compared with IFN-c; these levels were either further
decreased or unaffected by the presence of IFX in both groups
(data not shown). Thus, these results do not corroborate the
hypothesis that IL-10 plays a role in the decreased responses
induced in the presence of IFX.
Discussion
The mechanisms by which neutralizing anti-TNF-a antibodies,
such as IFX, reactivate latent TB are not yet fully known. In addi-
tion, there are no studies available regarding the effects of these
agents on the anti-Mtb responses of patients with moderate ⁄ severe
psoriasis.
Figure 2 Lymphocyte proliferative responses to M. tuberculosis
antigens. PBMCs isolated from TST+ severe psoriasis patients
(n = 11) and TST+ healthy individuals (n = 13) were stimulated
with SAg, Ag85B, ESAT-6 and PHA in the presence (filled dots)
or absence (empty dots) of infliximab (IFX, 5 lg ⁄mL) and prolifer-
ative responses were determined by [3H]thymidine incorporation.
Results are shown as stimulation index (SI); Mean counts of
unstimulated wells in the presence and absence of IFX for both
groups were not significantly different (not shown). *, P < 0.05;
**, P < 0.01, Wilcoxon matched pairs test.
Figure 3 Quantification of IFN-c-releasing cells. IFN-c-releasing
cells were quantified by ELISpot after overnight (16–18 h) PBMC
culture from untreated TST+ severe psoriasis patients (n = 10)
and TST+ healthy individuals (n = 13) stimulated with M. tubercu-
losis SAg, Ag85B, ESAT-6 ad PHA in the presence (filled dots)
or absence (empty dots) of infliximab (IFX, 5 lg ⁄mL). Each assay
was run in triplicates. Results are shown as mean ± SEM.
*, P < 0.05; **, P < 0.01, Wilcoxon matched pairs test. Counts of
spots from wells with non-stimulated cells were subtracted
[mean ± SE for patients: 2.3 ± 0.5 with and 1.6 ± 0.5 without
IFX (P > 0.05); controls: 3.5 ± 1.0 with and 2.8 ± 0.5 without IFX
(P > 0.05)].
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To address this, we performed in vitro studies in which IFX
(5 lg ⁄mL, within the therapeutic range concentration observed in
patients)15 was added to PBMC cultures from TST+ severe psoria-
sis patients and healthy individuals stimulated with different
mycobacterial antigens.
Our results show that IFX indeed affected some, but not all
aspects of the in vitro immune responses tested. T-cell activation
and function were impaired since LPR and IFN-c production to
mycobacterial antigens of both healthy individuals and psoriasis
patients were significantly decreased in the presence of IFX. Previ-
ous studies reported that IFX inhibited the in vitro IFN-c secretion
by activated intestinal T-lymphocytes from Crohn’s disease
patients.16 Hamdi et al.17 studied patients with other IMIDs
(mainly rheumatoid arthritis and ankylosing spondylitis) and also
observed that IFX decreased the in vitro T-cell activation induced
with mycobacterial (and other microbial) recall antigens. Saliu
et al.18 examined the anti-Mtb immune responses of healthy TST+
individuals and showed that IFX decreased T-cell activation and
the IFN-c responses to mycobacteria antigens. Interestingly, our
results showed that the effects of IFX were similar between healthy
individuals and psoriasis patients. Thus, our data corroborate pre-
vious reports showing the down modulatory effects on immunity
to Mtb of IFX and extend these to psoriasis patients. Similarly to
the findings of Saliu et al.,18 we could not detect any exacerbation
of IL-10 in the presence of IFX that might account for the down
regulatory effect of the antagonist. Thus, the combined effect of
TNF-a blockade and inhibition of IFN-c production seen in our
latently infected psoriasis patients could explain the higher risk to
TB reactivation, as pointed out earlier for the other IMIDs.19 In
fact, experimental studies provided evidence that the antimyco-
bacterial activity of human monocytes is affected by TNF-a
antagonists independent of IFN-c signalling, suggesting that
simultaneous deprivation of both cytokines may have an additive
or even synergistic effect.20 Another mechanism would be a tem-
porary decrease in the frequency of CD8+ Tem cells with antimy-
cobacterial activity, as shown in patients with RA undergoing IFX
therapy.21 However, Saliu et al.18 also observed that the ability to
control mycobacterial growth by 24 h whole blood cultures was
unaffected by IFX, indicating that innate or other unknown
immune bactericidal mechanisms may escape the anti-TNF effect.
In this same direction, our observation of intact IFN-c responses
in the overnight ELISpot assay suggests that these INF-c releasing
cells, probably Tem cells, were hardly affected by TNF-a blockade
and may contribute to some protection against TB reactivation.
We detected in both patients and healthy individuals a sizable fre-
quency (0.01–0.02% of the whole PBMC population) of T cells
that expressed IFN-c shortly after challenge with antigens either
shared by many mycobacteria (SAg and Ag85B) or more Mtb-
specific (ESAT-6, expressed by Mtb and a few other species such
as M. kansasii and M. marinum). This finding also suggests that
persistent or intermittent exposure to mycobacteria antigens occur
in our latently infected patients and healthy individuals. That these
cells are induced by continuous or repeated exposure to antigens
provided by mycobacteria acquired from the environment has
been demonstrated. Studies of health care workers with latent TB
due to recurrent exposure to TB patients demonstrated that these
individuals have high levels of anti-Mtb Tem cells on ELISpot that
persisted despite having being treated with isionazid for latent
TB.22 Recurrent exposure was the basis for these persistently high
responses. In addition, evidence that this subset of cells can medi-
ate protection against TB comes from studies on the mechanisms
underlying the efficacy of bacillus Calmette Guerin vaccination
during the first 10 years post vaccination (i.e. during childhood).
It has been shown that even small inocula of this attenuated myco-
bacteria elicited strong antigen-specific effector memory, but not
central memory, T-cell responses, and that this subset afforded
protection against further challenges with M. tuberculosis.23–25
These findings also help to explain data from our previous study
showing that the ELISpot responses to M. tuberculosis antigens
were strongly positive in TST non-responders severe psoriasis
Figure 4 Quantification of IFN-c production. IFN-c production
was quantified using ELISA in day 5 PBMC culture supernatants
from untreated TST+ severe psoriasis patients (n = 10) and TST+
healthy individuals (n = 12), stimulated with M. tuberculosis SAg,
Ag85B, ESAT-6 ad PHA in the presence (filled dots) or absence
(empty dots) of infliximab (IFX, 5 lg ⁄mL). Results are shown as
mean ± SEM. *, P < 0.05; **, P < 0.01, Wilcoxon matched pairs
test. Control wells with non-stimulated cells had undetectable
levels of the cytokine.
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patients in a similar fashion to their healthy TST-non-responders
counterparts, while both the LFP response and INF-c release into
supernatants, probably more related to central memory T-cell
responses, were strongly decreased.9
The rate of patients with IMID exposed to TNF-a antagonists
with reactivated TB in our setting was probably lower than
expected and may otherwise suggest that they still preserve some
degree of immunoprotection against bacillus reactivation. Our
present in vitro data are corroborated by our in vivo studies, where
the frequency of IFN-c-releasing Tem cells elicited by recall anti-
gens, including Mtb antigens, is measured by overnight ELISpot in
the peripheral blood of 13 severe psoriasis patients undergoing
TNF-a antagonists therapy. The preliminary data show that the
frequencies were augmented in a subset of these patients (8 of the
13 patients) after 7 weeks on therapy (LCM Ortigosa, LCR Silva &
G Benard, unpublished data). We thus suggest that in TB endemic
or tropical areas the recurrent exposure to environmental myco-
bacteria, either pathogenic or not,26 would result in sufficient lev-
els of IFN-c-releasing Tem cells to keep in check, at least partially,
TB reactivation in a proportion of patients even in a TNF-a
deficient microenvironment.
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